Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4144 in ASCVD and CKD with inflammation
NCT06675175Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing AZD4144 with Placebo (2 arms). Primary endpoints: Adverse Events at 8 weeks and Interleukin-6 at 4 weeks. Started Dec 2024; status: completed.
02
Drugs
AZD4144
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06675175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675175.